Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation

Journal of Drug Targeting

Volumn 14, Issue 9, 2006, Pages 652-661

  Di Stefano, Antonio ^a   Sozio, Piera ^a   Iannitelli, Antonio ^a   Marianecci, Carlotta ^b   Santucci, Eleonora ^b   Carafa, Maria ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

L Dopa; L Dopa prodrugs; Liposomes; Microdialysis; Parkinson's disease

Indexed keywords

(O,O DIACETYL)LEVODOPA METHYL ESTER; ANTIPARKINSON AGENT; BUFFER; DIAMIDE; DOPAMINE; FUMARIC ACID; LEVODOPA; LIPOSOME; MALEIC ACID; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS SOLUTION; ARTICLE; CIS ISOMER; CONTROLLED STUDY; CORPUS STRIATUM; DIALYSATE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENCAPSULATION; MALE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT;

AMIDES; ANIMALS; ANTIPARKINSON AGENTS; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; DRUG COMPOUNDING; DRUG STABILITY; ELECTROCHEMISTRY; FUMARATES; HUMANS; HYDROLYSIS; INDICATORS AND REAGENTS; LEVODOPA; LIPOSOMES; MALE; MALEATES; MASS SPECTROMETRY; MICRODIALYSIS; PARTICLE SIZE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33750802483     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.1080/10611860600916636     Document Type: Article

References (37)

1. Abercrombie, ED and Finlay, JM.(1991) Techniques in the behavioral and neural sciences. Amsterdam: Elsevier Science Ltd.
2. Allen, TM. (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future Drugs, 56, pp. 747-756.
3. Amidon, GL and Lennernas, H and Shah, VP and Crison, JR. (1995) A theoretical basis for a biopharmaceutical drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability Pharm Res, 12, pp. 413-420.
4. Beal, MF. (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses Ann Neurol, 31, pp. 119-130.
5. Blanchet, PJ and Allard, P and Gregoire, L and Tardif, F and Bedard, PJ. (1996) Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients Can J Neurol Sci, 23, pp. 189-193.
6. Bodor, N and Sloan, KB and Higuchi, T and Sasahara, K. (1977) Improved delivery through biological membranes. 4. Prodrugs of L-dopa J Med Chem, 20(11), pp. 1435-1445.
7. Cannazza, G and Di Stefano, A and Mosciatti, B and Braghiroli, D and Baraldi, M and Pinnen, F and Sozio, P and Benfatti, C and Parenti, C. (2005) Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of L-DOPA prodrugs by means of HPLC-EC J Pharm Biomed Anal, 36, pp. 1079-1084.
8. Carafa, M and Santucci, E and Alhaique, F and Coviello, T and Murtas, E and Riccieri, FM and Lucania, G and Torrisi, MR. (1998) Preparation and properties of new unilamellar non-ionic/ionic surfactant vesicles Int J Pharm, 160, pp. 51-59.
9. Chonn, A and Cullis, PR. (1995) Recent advances in liposomal drug-delivery systems Curr Opin Biotechnol, 6, pp. 698-708.
10. Cooper, DR and Marrel, C and Van de Waterbeemd, H and Testa, B and Jenner, P and Marsden, CD. (1987) L-Doppa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease J Pharm Pharmacol, 39, pp. 627-635.
11. Da Prada, M and Keller, HH and Fieri, L and Kettler, L and Haefely, WE. (1984) The pharmacology of Parkinson's disease: Basic aspects and recent advances Experientia, 40, pp. 1165-1172.
12. Di Stefano, A and Mosciatti, B and Cingolani, GM and Giorgioni, G and Ricciutelli, M and Cacciatore, I and Sozio, P and Claudi, F. (2001) Dimeric L-Dopa derivatives as potential prodrugs Bioorg Med Chem Lett, 11, pp. 1085-1088.
13. Di Stefano, A and Carafa, M and Sozio, P and Pinnen, F and Braghiroli, D and Orlando, G and Cannazza, G and Ricciutelli, M and Marianecci, C and Santucci, E. (2004) Evaluation of rat striatal L-Dopa and DA concentration after intraperitoneal administration of L-Dopa prodrugs in liposomal formulations J Control Release, 99, pp. 293-300.
14. Dressman, JB and Reppas, C. (2000) In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur J Pharm Sci, 11(S2), pp. S63-S80.
15. Farghaly, AO. (1998) Cyclic amide derivatives as potential prodrugs. Synthesis and evaluation of N-hydroxymethylphthalimide esters of some non-steroidal anti-inflammatory carboxylic acid drugs Eur J Med Chem, 33, pp. 123.
16. Galia, E and Nicolaides, E and Hörter, D and Löbenberg, R and Reppas, C and Dressman, JB. (1998) Evaluation of various dissolution media for predictiong in vivo performance of class I and II drugs Pharm Res, 15, pp. 698-705.
17. Gooitzen, A and Lameris, T and Van den Meiracker, AH and Man in't Veld, AJ and Boomsma, F. (1999) Sensitive and specific method for the simultaneous determination of natural and synthetic catecholamines and 3,4-dihydroxyphenylglycol in microdialysis samples J Chromatogr B, 730, pp. 213-219.
18. Görner, T and Gref, R and Michenot, D and Sommer, F and Tran, MN and Dellacherie, E. (1999) Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymeric matrix J Control Release, 57, pp. 259-268.
19. Grant, DJW and Higuchi, T.(1990) Solubility and partitioning into water. In Solubility behaviour of organic compounds. (pp. 164-175). New York: Wiley.
20. Gregoriadis, G and Senior, J and Wolff, B and Kirby, C. (1984) Fate of liposomes in vivo: Control leading to targeting Life Sci, 82, pp. 243-266.
21. Gundert-Remy, U and Hildebrand, R and Stiehl, A and Weber, E and Zurcher, G and Da Prada, M. (1983) Intestinal absorption of levodopa in man Eur J Clin Pharmacol, 25, pp. 69-72.
22. Ho, NFH and Ganesan, MG and Weiner, ND and Flynn, GL. (1985) Mechanism of topical delivery of liposomally entrapped drugs J Control Release, 2, pp. 61-65.
23. Ihara, M and Nakajima, S and Hisaka, A and Tsuchiya, Y and Sakuma, Y and Suzuki, H and Kitani, K and Yano, M. (1990) Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4-pivaloyloxyphenyl)alanine J Pharm Sci, 79, pp. 703-708.
24. Jonkers, N and Sarre, S and Ebinger, G and Michotte, Y. (2001) Benserazide decreases central AADC activity, extracellular dopamine levels and levodopa decarboxylation in striatum of the rat J Neural Transm, 108, pp. 559-570.
25. Kim, S and Scheerer, S and Geyer, MA and Howell, SB. (1990) Direct cerebrospinal fluid delivery of an antiretroviral agent using multivesicular liposomes J Infect Dis, 162, pp. 750-752.
26. Koller, WC.(1992) Handbook of Parkinson's disease 2nd ed. USA. Dekker, New York
27. Mack, F and Boenisch, H. (1979) Dissociation constants and lipophilicity of catecholamines and related compounds NS Arch Pharmacol, 310, pp. 1-9.
28. Paxinos, G and Watson, C.(1986) The rat brain in stereotaxic coordinates. Orlando: Academic Press.
29. Santucci, E and Carafa, M and Coviello, T and Murtas, E and Riccieri, FM and Alhaique, F and Modesti, A and Modica, A. (1996) STP Pharm Sci, 6, pp. 29-32.
30. Skinner, MK. (1992) Intrinsic dissolution rate and solubility studies on josamicin, a macrolide antibiotic Int J Pharm, 88, pp. 151-158.
31. Streng, WH.(2001) Experimental procedures and example. In Characterization of compounds in solution - theory and practice. (pp. 161-180). New York: Kluver Academic Plenum Publisher.
32. Tolosa, E and Marti, MJ and Valldeoriola, F and Molinuevo, JL. (1998) History of levodopa and dopamine agonists in Parkinson's disease treatment Neurology, 50, pp. S2-10.
33. Wang, H and Lee, J and Tsai, M and Lu, H and Hsu, W. (1995) Synthesis and pharmacological activities of a novel tripeptide mimetic dopamine prodrug Bioorg Med Chem Lett, 5, pp. 2195-2918.
34. Yalkowsky, SH and Banerjee, S.(1992) Aqueous solubility: Methods of estimation for organic compounds. New York: Marcel Dekker.
35. Yalkowsky, SH and Morzowich, W.(1980) Drug design. New York: Academic.
36. Yurasov, VV and Kucheryanu, VG and Kudrin, VS and Zhigal'tsev, NikushkinEV, IV and Sandalov, YG and Kaplun, AP and Shvets, VI. (1997) Effect of long-term parenteral administration of empty and 1-DOPA liposomes on the turnover of dopamine and its metabolites in the striatum of mice with experimental Parkinson's syndrome Byull Eksp Biol Med, 123, pp. 126-129.
37. Zappia, M and Annesi, G and Nicoletti, G and Arabia, G and Annesi, F and Messina, D and Pugliese, P and Spadafora, P and Tarantino, P and Carrideo, S and Civitelli, D and De Marco, EV and Ciro-Candiano, IC and Gambardella, A and Quattrone, A. (2005) Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: An exploratory study Arch Neurol, 62, pp. 601-605.